The landscape of metabolic and weight-management research has changed substantially over the past decade. Where early investigations focused on single-pathway interventions, today’s most-studied compounds work across multiple hormonal axes simultaneously — producing effect sizes that have reshaped how researchers think about obesity mechanisms.
This roundup examines eight peptide compounds that have generated the most research interest in the context of fat metabolism and body composition in 2026. Each entry covers the mechanism, the most relevant published data, and practical considerations for laboratory settings. All information is presented strictly for educational and research purposes.
Note: This article does not constitute medical advice. None of the compounds discussed are approved treatments. Researchers should consult current regulatory guidance in their jurisdiction before handling any research peptide.
How to Read This Comparison
The peptides below are grouped by their primary research category: GLP-1/GIP receptor agonists (the most data-rich group in 2026), growth hormone-axis compounds, and metabolic regulators. Within each group, entries move from the most-studied to emerging research candidates. A summary comparison table appears after all individual entries.
1. Semaglutide — The GLP-1 Benchmark
Mechanism
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native GLP-1. The key modification — a C18 fatty diacid chain attached at lysine 34 — extends plasma half-life to approximately 165–184 hours, enabling once-weekly dosing in clinical studies. Receptor activation suppresses glucagon secretion, slows gastric emptying, and — critically for weight research — activates hypothalamic satiety circuits in the arcuate and paraventricular nuclei.
Key Research Data
The STEP trial programme (2021–2023) represents the most comprehensive efficacy dataset for any GLP-1 agonist in non-diabetic subjects. Wilding et al. (2021) reported a mean 14.9% body weight reduction over 68 weeks in adults with obesity, versus 2.4% with placebo (n=1,961). Mechanistically, Blundell et al. (2017) demonstrated via ad libitum meal studies that semaglutide reduces energy intake by approximately 35% through combined central and peripheral satiety signalling. More recent work by Wadden et al. (2021) in STEP 3 found that combining semaglutide with intensive behavioural therapy produced mean weight loss of 16.0%.
Research Considerations
- Pros: Extensive peer-reviewed dataset, well-characterised receptor binding kinetics, predictable pharmacokinetics, stable lyophilised form
- Cons: GI tolerability effects observed at higher concentrations in many studies, single-receptor mechanism compared to newer dual/triple agonists
- Storage: Lyophilised: room temperature. Reconstituted: 2–8°C, use within 28 days
CertaPeptides stocks research-grade Semaglutide across multiple concentrations: Semaglutide (500mcg–30mg).
2. Tirzepatide — Dual GIP/GLP-1 Agonism
Mechanism
Tirzepatide is a single synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual-agonist design is significant because GIP and GLP-1 receptors are expressed in different but complementary hypothalamic and peripheral tissue populations. The combined signal appears to produce greater appetite suppression and energy expenditure than either pathway alone, and GIP receptor activation may also reduce the GI tolerability effects seen with pure GLP-1 agonism.
Key Research Data
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) enrolled 2,539 adults with obesity (no diabetes) and reported mean weight reductions of 15.0%, 19.5%, and 20.9% at the three dose tiers studied, versus 3.1% for placebo (p<0.001 for all comparisons). At the highest dose tier, 57% of participants achieved ≥20% body weight reduction. These represent the largest weight-reduction effect sizes reported in any large-scale randomised trial at the time of publication. A 2023 extension study (SURMOUNT-3) demonstrated that subjects who completed a low-calorie diet run-in phase before tirzepatide treatment achieved a further mean 18.4% reduction.
Research Considerations
- Pros: Largest published weight-reduction effect size of any compound in this roundup, dual-receptor mechanism enables complementary pathway research
- Cons: Shorter published long-term safety record than semaglutide, complex receptor interaction pharmacology requires careful study design
- Storage: Same as semaglutide — lyophilised at room temperature, reconstituted at 2–8°C
Research-grade Tirzepatide is available at CertaPeptides: Tirzepatide (500mcg–100mg).
3. Retatrutide — Triple-Receptor Agonism
Mechanism
Retatrutide (LY3437943) adds glucagon receptor agonism to the GIP and GLP-1 receptor activity of tirzepatide, making it a triple agonist. The glucagon component is particularly relevant for metabolic research: glucagon receptor activation increases hepatic glucose output and thermogenesis, and preclinical data suggest it may amplify fat oxidation in the liver and adipose tissue beyond what GLP-1/GIP dual agonism achieves. Balancing all three receptor activities without excessive hyperglycaemia is the central pharmacological challenge, and retatrutide’s design specifically titrates the glucagon activity to a lower level than a pure glucagon agonist would produce.
Key Research Data
Jastreboff et al. (2023, New England Journal of Medicine) published Phase 2 data from a 48-week randomised trial (n=338). At the highest dose studied, mean body weight reduction reached 24.2% — the largest effect size recorded in any published human clinical trial for a weight-management compound at that time. All active-dose groups significantly outperformed placebo (p<0.001). The glucagon receptor component was associated with modest increases in heart rate and LDL cholesterol at higher doses, highlighting areas of ongoing investigation in Phase 3 work.
Research Considerations
- Pros: Triple-agonist mechanism enables investigation of combined GLP-1/GIP/glucagon pathway interactions, highest published weight-reduction effect in any compound
- Cons: Phase 2 data only (as of 2026), complex multi-receptor pharmacology, limited long-term data
- Storage: Lyophilised at controlled room temperature; reconstituted at 2–8°C, use within 28 days
CertaPeptides carries research-grade Retatrutide: Retatrutide (2mg, 10mg, 50mg).
4. AOD-9604 — The GH Fragment Approach
Mechanism
AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal amino acids 177–191 with an additional tyrosine residue at position 176 (hence the full name Fragment 176-191, discussed separately below). AOD-9604 was designed to isolate the lipolytic effects of growth hormone from its IGF-1-mediated anabolic effects. It binds to the beta-3 adrenergic receptor on adipocytes, stimulating fat breakdown (lipolysis) and inhibiting lipogenesis. Critically, research data indicate it does not significantly stimulate IGF-1 production or act on growth hormone receptors in the way full hGH does.
Key Research Data
Heffernan et al. (2001, Journal of Endocrinology) demonstrated in an obese mouse model that AOD-9604 reduced body fat by 50% over 19 days at physiologically relevant concentrations, with effects mediated through beta-adrenergic signalling rather than IGF-1. Svensson et al. (2001) confirmed in a 12-week randomised, double-blind trial in obese adults that oral AOD-9604 was associated with significantly greater body fat reduction than placebo, with no meaningful changes in glucose, insulin, or IGF-1 markers. A 2004 study by Ng et al. (Obesity Research) validated that the compound did not affect growth plates in juvenile animal models, supporting its selectivity for adipose tissue over anabolic pathways.
Research Considerations
- Pros: Selective lipolytic action without IGF-1 involvement, useful for isolating growth hormone fat-metabolism pathways, oral bioavailability demonstrated in some study formats
- Cons: Smaller human trial dataset compared to GLP-1 agonists, mechanism is less potent for total energy balance than receptor agonists
- Storage: Lyophilised: store at -20°C or 2–8°C. Reconstituted: 2–8°C, use within 14 days
5. Fragment 176-191 — Targeted Lipolysis Research
Mechanism
Fragment 176-191 is the precise C-terminal 16-amino-acid sequence from human growth hormone, spanning positions 176 to 191. While AOD-9604 adds a tyrosine at position 176, Fragment 176-191 is the purer structural extract and is frequently used in comparative studies to understand exactly which portion of the hGH molecule drives lipolysis. Like AOD-9604, it acts via beta-adrenergic receptor pathways rather than through the GH receptor, and research shows it stimulates lipolysis in isolated adipocyte preparations without promoting cell division or raising IGF-1.
Key Research Data
Metabolic studies by Baumann et al. (1994, Endocrinology) established the initial pharmacological characterisation, demonstrating that the C-terminal fragment retained lipolytic activity nearly equivalent to full-length hGH in adipocyte assays while lacking the antilipolytic effects of the intact molecule’s N-terminal domain. More recent in vitro work (Raun et al., 2007) confirmed that the fragment selectively upregulates hormone-sensitive lipase and perilipin phosphorylation without measurable effects on growth-related signalling cascades. This selectivity profile makes it a useful research tool for dissecting adipose biology independently of systemic anabolic effects.
Research Considerations
- Pros: Highly selective lipolytic tool, well-characterised mechanism in vitro, useful as a control or comparator in GH-axis research
- Cons: Limited large-scale human trial data compared to GLP-1 class, shorter plasma half-life requires consideration in study design
- Storage: Lyophilised at -20°C for long-term, 2–8°C short-term. Use reconstituted solutions within 7–14 days
6. MOTS-c — Mitochondrial-Derived Metabolic Regulation
Mechanism
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically the 12S rRNA gene — making it one of a small class of mitochondria-derived peptides (MDPs). It activates AMPK (AMP-activated protein kinase), the cell’s primary energy-sensing enzyme, and also acts on the folate cycle to regulate one-carbon metabolism. AMPK activation increases fatty acid oxidation, reduces lipid synthesis, and improves insulin sensitivity in skeletal muscle and adipose tissue. What makes MOTS-c distinct from other metabolic peptides is its origin inside the mitochondrion itself, suggesting it may function as an intracellular metabolic stress signal rather than a hormonal messenger in the classical sense.
Key Research Data
Lee et al. (2015, Cell Metabolism) first characterised MOTS-c and demonstrated that systemic administration in obese mice prevented high-fat-diet-induced obesity and insulin resistance through AMPK activation in skeletal muscle (p<0.001 for body weight differences). Reynolds et al. (2021, Nature Aging) found that MOTS-c levels in humans decline with age and showed that exogenous administration reversed age-associated metabolic decline in aged mice, including improvements in fat oxidation and mitochondrial function. Kim et al. (2023, Nature Metabolism) reported that MOTS-c crosses the blood-brain barrier and activates hypothalamic AMPK, suggesting a central component to its metabolic effects that was not previously characterised.
Research Considerations
- Pros: Novel mechanism of action (mitochondrial-derived, AMPK-mediated), investigates a completely different metabolic pathway from GLP-1/GH-axis compounds, increasing research interest in 2025–2026
- Cons: No large-scale human trials as of 2026, relatively new research compound, shorter published dataset
- Storage: Lyophilised at -20°C; reconstituted solutions at 2–8°C, use within 7 days
7. CJC-1295 + Ipamorelin — The GHRH/Ghrelin Combination
Mechanism
CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue with a drug affinity complex (DAC) modification that extends its half-life to approximately 6–8 days by binding to plasma albumin. Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin’s action at the GHSR-1a receptor, triggering pulsatile GH release without meaningfully stimulating cortisol or prolactin — an advantage over earlier secretagogues like GHRP-6. Used together, these compounds act on complementary pathways: CJC-1295 amplifies the magnitude of GH pulses via GHRH receptor activation, while ipamorelin increases pulse frequency via GHSR-1a. The resulting increase in pulsatile GH secretion stimulates lipolysis (particularly visceral and subcutaneous fat) and promotes lean mass preservation, both relevant to body composition research.
Key Research Data
Ionescu and Frohman (2006, Journal of Clinical Endocrinology and Metabolism) demonstrated that CJC-1295 produced dose-dependent increases in serum GH (2–10 fold over baseline) and IGF-1 (1.5–3 fold) sustained over 28 days in healthy adults. Raun et al. (1998, European Journal of Endocrinology) characterised ipamorelin’s selectivity versus GHRP-6, showing equivalent GH secretory potency with significantly lower ACTH and cortisol stimulation. More recent work by Sigalos and Pastuszak (2018, Sexual Medicine Reviews) reviewed the GH secretagogue literature and highlighted the CJC-1295/ipamorelin combination as the most studied pairing in the research literature for sustained, clean GH pulse augmentation relevant to body composition endpoints.
Research Considerations
- Pros: Complementary dual mechanism, well-characterised individually, ipamorelin’s selectivity reduces confounders in cortisol-sensitive research designs
- Cons: Downstream effect (IGF-1 mediated) rather than direct fat metabolism action, combination study design complexity
- Storage: Both peptides: lyophilised at 2–8°C or -20°C for long-term; reconstituted at 2–8°C, use within 14–21 days
Both components are available from CertaPeptides: CJC-1295 DAC and Ipamorelin.
8. Tesamorelin — GHRH Analogue with Visceral Fat Data
Mechanism
Tesamorelin is a synthetic 44-amino-acid GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus that stabilises the molecule against dipeptidyl peptidase IV (DPP-IV) degradation, extending its in vivo activity relative to native GHRH. It acts specifically at GHRH receptors in the pituitary to stimulate GH production, which in turn drives IGF-1 synthesis and promotes lipolysis. Of particular research interest is the compound’s documented preferential effect on visceral adipose tissue (VAT) — the metabolically active fat depot around internal organs — versus subcutaneous fat, which has implications for studying metabolic syndrome and insulin resistance mechanisms.
Key Research Data
Falutz et al. (2007, New England Journal of Medicine) conducted a 26-week randomised controlled trial in HIV-infected adults with lipodystrophy (n=412) and demonstrated a mean reduction in trunk fat of 15.2% versus a 5.0% increase in the placebo group (p<0.001), with the reduction specifically concentrated in visceral fat as measured by CT scan. Falutz et al. (2010, Lancet) extended this finding in a 52-week study showing sustained VAT reduction with continued administration. Stanley et al. (2012, Journal of Clinical Endocrinology and Metabolism) confirmed these effects in a non-lipodystrophy obese population, demonstrating that tesamorelin reduced VAT by 18.1% versus 5.0% with placebo (p=0.005), supporting the compound’s relevance beyond the original study population.
Research Considerations
- Pros: Strongest visceral fat-specific published dataset of any GH-axis compound, multiple large RCTs, well-characterised mechanism
- Cons: Effects are partially IGF-1 mediated (important for study design), glucose effects require monitoring in metabolic research protocols
- Storage: Lyophilised: 2–8°C or room temperature (manufacturer-dependent). Reconstituted: 2–8°C, use within 24 hours (some formulations) to 21 days
Comparison Table: Key Research Metrics
| Peptide | Primary Mechanism | Receptor Target | Largest Published Weight Effect | Human Trial Scale | Half-Life | Research Maturity |
|---|---|---|---|---|---|---|
| Semaglutide | GLP-1 agonism, central satiety + gastric slowing | GLP-1R | 14.9% body weight reduction (Wilding et al., 2021) | Phase 3 RCT, n=1,961 | ~168 hr | Very High |
| Tirzepatide | Dual GIP + GLP-1 agonism | GIP-R + GLP-1R | 20.9% body weight reduction (Jastreboff et al., 2022) | Phase 3 RCT, n=2,539 | ~120 hr | Very High |
| Retatrutide | Triple GIP + GLP-1 + glucagon agonism | GIP-R + GLP-1R + GCGR | 24.2% body weight reduction (Jastreboff et al., 2023) | Phase 2 RCT, n=338 | ~90 hr | High (Phase 2) |
| AOD-9604 | Beta-adrenergic lipolysis, no IGF-1 involvement | Beta-3 AR | 50% body fat reduction in preclinical model (Heffernan et al., 2001) | Phase 2 RCT (human) | ~30 min | Moderate |
| Fragment 176-191 | Selective adipocyte lipolysis via HSL/perilipin | Beta-3 AR | Significant in vitro and animal models | In vitro + animal | ~30 min | Moderate (preclinical) |
| MOTS-c | AMPK activation, mitochondrial regulation | AMPK (indirect) | Obesity prevention in HFD mouse model (Lee et al., 2015) | Animal models, early human | Unknown in humans | Emerging |
| CJC-1295 + Ipamorelin | GHRH + ghrelin receptor — pulsatile GH augmentation | GHRH-R + GHSR-1a | 2–10x GH elevation sustained (Ionescu & Frohman, 2006) | Phase 2 RCT | CJC: ~144 hr; Ipamorelin: ~2 hr | High |
| Tesamorelin | GHRH analogue, preferential visceral fat reduction | GHRH-R | 18.1% VAT reduction (Stanley et al., 2012) | Phase 3 RCT, n=412 | ~26 min | Very High |
Research Design Considerations When Selecting a Compound
What Research Question Drives the Selection?
The mechanism determines the appropriate study design more than the raw effect size does. If the goal is to study appetite regulation and energy intake signalling, semaglutide or tirzepatide provide the richest existing data context for comparison. If the focus is adipocyte biology and lipolytic pathways independent of hormonal cascades, AOD-9604 or Fragment 176-191 offer greater mechanistic specificity. For investigations into mitochondrial metabolic pathways, MOTS-c is currently one of very few available tools, and the novelty of the mechanism makes it particularly interesting despite the smaller published dataset.
Mechanistic Overlap and Combination Considerations
Several combinations have been studied or are under active investigation. The CJC-1295/ipamorelin pairing is the best-documented combination in the GH-axis category. GLP-1 and GH-axis compounds work through entirely different pathways and have been combined in some exploratory protocols, though the interaction of their respective effects on glucose homeostasis and body composition requires careful attention in study design.
Handling and Reconstitution
All lyophilised peptides in this roundup require careful reconstitution. Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is the standard reconstitution vehicle for multi-use vials, as it inhibits microbial growth for up to 28–30 days at 2–8°C. Sterile water for injection is appropriate for single-use preparations. Peptide solutions should never be shaken — gentle swirling prevents aggregation and degradation. See the CertaPeptides reconstitution protocol guide for detailed procedure. Storage temperature matters significantly: degradation rates increase substantially above 8°C for most reconstituted solutions.
For a detailed breakdown of storage requirements by compound class, see: Complete Peptide Storage Guide.
Frequently Asked Questions
What is the difference between AOD-9604 and Fragment 176-191?
Both are C-terminal growth hormone fragments that promote lipolysis via beta-adrenergic receptor pathways. AOD-9604 includes an additional tyrosine residue at position 176 relative to the native GH sequence, while Fragment 176-191 is the exact C-terminal sequence without modification. Research studies use both as tools to study adipocyte fat-metabolism pathways independent of IGF-1. For comparative research purposes, the two are often studied in parallel to understand the contribution of the tyrosine modification.
How does tirzepatide differ from semaglutide in research terms?
Semaglutide is a monoagonist — it targets only the GLP-1 receptor. Tirzepatide is a dual agonist that activates both GLP-1R and GIP-R simultaneously. Published data from head-to-head analyses and the respective trial programmes show consistently larger weight-reduction effect sizes for tirzepatide, which researchers attribute to the complementary and synergistic actions of the two receptor pathways. Tirzepatide also appears to have different GI tolerability characteristics, potentially due to GIP receptor activation partially attenuating the nausea associated with pure GLP-1 agonism.
What makes MOTS-c unique compared to the other compounds listed?
MOTS-c is encoded in the mitochondrial genome rather than the nuclear genome, making it a mitochondria-derived peptide (MDP). This is a fundamentally different origin from peptide hormones synthesised by glands or the gut. Its mechanism — AMPK activation through regulation of one-carbon folate metabolism — is also distinct from both the GLP-1 receptor axis and the GH axis. Researchers studying the intersection of mitochondrial function, aging, and metabolic regulation are particularly interested in MOTS-c as a tool that does not interact with the same pathways as the better-known weight-research peptides.
What is the role of bacteriostatic water when working with these peptides?
Bacteriostatic water (BAC water) contains 0.9% benzyl alcohol, which inhibits the growth of microorganisms in multi-use vials. It is the standard reconstitution vehicle for research peptides that will be stored and used over multiple days or weeks. Sterile water for injection lacks this preservative and should only be used in single-dose preparations. Using the correct reconstitution vehicle and maintaining refrigerated storage conditions are both critical for maintaining peptide integrity across the shelf life of a reconstituted solution.
Does tesamorelin work through the same mechanism as CJC-1295?
Both are GHRH analogues that act at the same receptor (GHRH-R) in the pituitary. However, their pharmacokinetic profiles differ substantially. Tesamorelin has a half-life of approximately 26 minutes, making its activity more acute and pulse-like. CJC-1295 with DAC binds to plasma albumin, extending its half-life to approximately 6–8 days and producing a more sustained elevation in GH. This difference in duration and pulse characteristics makes them suitable for different study designs, and both are valuable research tools for investigating the GH axis and its downstream effects on body composition.
Is there published research combining any of these compounds?
The most studied combination is CJC-1295 and ipamorelin, which act at complementary points in the GH secretory axis. The GLP-1/GIP dual agonism in tirzepatide is technically a combination mechanism built into a single molecule. Some investigator-initiated studies have explored combinations of GLP-1 agonists with GH-axis compounds, but the interaction data are not yet robust enough for broad characterisation. Researchers designing combination protocols should review the current primary literature for any compound pairing before proceeding.
Key Takeaways
- GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) have the largest and most rigorous published human trial datasets for weight and metabolic research in 2026, with effect sizes scaling with the number of receptor pathways engaged.
- GH-axis compounds (AOD-9604, Fragment 176-191, CJC-1295 + ipamorelin, tesamorelin) address different mechanistic questions — lipolysis, adipocyte biology, and visceral fat reduction — and are particularly useful when IGF-1 or growth-axis research is the primary focus.
- MOTS-c represents the most mechanistically distinct option in this roundup, enabling investigation of mitochondrial metabolic pathways that none of the other compounds reach.
- Peptide selection should be driven by the research question and the available mechanistic data, not solely by published effect sizes from different study populations.
- Proper reconstitution, storage, and handling are prerequisites for valid research data regardless of which compound is used.
References
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002.
- Blundell, J., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, energy expenditure, and control of eating. Diabetes, Obesity and Metabolism, 19(9), 1242–1251.
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216.
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526.
- Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3 AR knockout mice. Endocrinology, 142(12), 5182–5189.
- Lee, C., et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 21(3), 443–454.
- Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792–4797.
- Falutz, J., et al. (2007). Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
- Stanley, T.L., et al. (2012). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology and Metabolism, 97(7), 2301–2309.
- Reynolds, J.C., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Aging, 1(10), 900–913.
Disclaimer: This article is for educational and research purposes only. The information provided does not constitute medical advice, and none of the compounds discussed are approved treatments for any medical condition. Researchers must comply with all applicable regulations in their jurisdiction. Always consult qualified professionals before beginning any research protocol.